Cognition
Memory, attention, processing speed and recovery after neurological injury require different tests and populations. One score cannot stand for “brain performance”.
Claim review · O-033
Peptide cognition, mood and sleep claims
Small regional studies are not a general nootropic verdict. Semax, Selank and DSIP have different claims, evidence histories and uncertainties.
Evidence for Semax, Selank and DSIP does not support dependable general claims to improve cognition, mood or sleep. The literature is small, often regional or historic, and has limited independent replication. Product identity and intranasal or injectable safety add separate gaps.
A physiological signal, small symptom score or study in a narrow neurological population cannot establish everyday cognitive enhancement, anxiety treatment or better sleep in generally healthy users. Each outcome needs its own controlled human evidence.
Claim separation
Cognition, mood and sleep are three evidence questions
Mood
Anxiety symptoms, depressive symptoms, stress and wellbeing are not interchangeable. Diagnosis, comparator and validated scales matter.
Sleep
Sleep onset, duration, architecture, awakenings and next-day function may move independently. Subjective sleep is not the same as polysomnography.
Product quality
A paper about a molecule does not verify a spray or vial. Identity, amount, degradation, impurities and microbiological quality remain product questions.
Evidence comparison
What the compound literatures can support
| Compound | Common claim | Evidence pattern | Current conclusion |
|---|---|---|---|
| Semax | Improves cognition or neurological recovery | Small, regionally concentrated studies and mechanistic research | Insufficient for general cognitive enhancement; independent replication is limited |
| Selank | Reduces anxiety or improves mood | Small regional studies, limited transparent replication | Low certainty; does not establish routine treatment or consumer spray claims |
| DSIP / emideltide | Improves sleep | Small historic studies with varied populations and outcomes | No dependable modern evidence for a general sleep benefit |
Method check
Why the evidence can look stronger than it is
Search results may contain many citations without many independent experiments.
Translations, conference records, narrative reviews and papers from related teams can amplify a finding without adding a new controlled population. Older sleep studies may use diagnostic labels or recording methods that do not map cleanly to current practice.
A useful appraisal counts independent cohorts, checks randomisation and blinding, looks for prespecified outcomes and compares effect sizes with harms and missing data. It also asks whether participants had a diagnosed condition or were healthy volunteers.
PopulationCondition versus enhancement
OutcomeValidated and prespecified
ReplicationIndependent and transparent
ProductMatched formulation and route
Safety evidence
Absence of a large harm record is not proof of safety
The FDA identifies limited safety information for compounded Semax and Selank, and potential concerns related to peptide impurities or immune responses. Emideltide has also entered the US federal compounding review process. These assessments do not decide UK status, but they show why sparse adverse-event reporting cannot support a safety conclusion.
Small or poorly monitored populations may miss uncommon, delayed or product-specific harms. Intranasal and injectable products also need appropriate microbiological and formulation controls.
Decision boundary
What remains unknown
- Whether Semax improves meaningful cognitive outcomes in independently replicated trials.
- Whether Selank improves diagnosed anxiety or mood outcomes beyond placebo.
- Whether DSIP improves modern objective and patient-important sleep measures.
- How risks change with route, duration and concurrent medicines.
- The frequency of uncommon immune, neurological or cardiovascular effects.
- Whether any particular vial or spray contains a stable, sterile product at the stated amount.
Appraisal test
What a more informative cognition, mood or sleep trial needs
A useful trial would register a primary outcome before enrolment, conceal allocation, use a credible placebo and report who remained blinded. It would separate participants with a diagnosed condition from healthy volunteers seeking enhancement. Follow-up should last long enough to assess persistence, withdrawal and delayed harms.
Cognition trials should control for practice effects. Mood trials should use validated scales and report clinically meaningful response, not only average score changes. Sleep trials should pair patient-reported outcomes with objective measures when appropriate and report next-day function. Independent replication should use a clearly characterised formulation.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA: bulk substances with significant safety risks | Current federal safety concerns and data gaps for Semax and Selank. | It does not determine effectiveness or classify a UK product. | |
| FDA: July 2026 PCAC meeting | Semax and emideltide were reviewed in the federal compounding process. | Committee consideration is not a UK marketing authorisation or a general efficacy finding. | |
| ClinicalTrials.gov | A registry route for checking prospectively registered human studies and outcomes. | A registration alone is not a result and incomplete registration can still bias a literature. | |
| MHRA products database | The official route to check current UK marketing authorisations. | Absence from one name search does not verify a seller claim or product content. |
Continue the investigation
Read the connected evidence
- the Semax evidenceInspect population, outcome and replication limits.
- the Selank evidenceSeparate small anxiety studies from general mood claims.
- the DSIP sleep evidenceCompare historic sleep studies with current evidence standards.
- the cognition and sleep claims assessedSee how the evidence library records these claims at claim level.
Quick answers
Frequently asked questions
Is Semax a proven nootropic?
No. Its literature is small and regionally concentrated, with limited independent replication for general cognitive enhancement.
Does Selank treat anxiety?
Small studies create a research signal, but the evidence is too limited to establish routine treatment or a general consumer claim.
Does DSIP improve sleep?
Historic small studies do not provide dependable modern evidence for better sleep across common sleep problems.
Are these compounds authorised medicines in the UK?
No UK marketing authorisations were identified for Semax, Selank or DSIP when this draft was checked. Verify the current MHRA database.
Does limited harm reporting mean they are safe?
No. Small exposure counts, uncertain product identity and weak surveillance can leave important harms unmeasured.
What remains unknown?
Independent efficacy, long-term harms, route-specific risks and the identity and quality of individual products remain unknown.
Editorial experience
From our work: how we checked this page
For topical-map item O-033, Peptide cognition, mood and sleep claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 7 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.